PHIL-IONP Embolic Heating for Repeatable Tumor Ablation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing magnetic fluid hyperthermia (MFH) treatments for vascularized solid tumors face challenges due to the rapid diffusion of injected nanoparticle solutions, leading to lower heating efficacy and inconsistent treatment outcomes, as the concentration of magnetic nanoparticles at the targeted region is not maintained over time.
Innovation Solution
A shelf-stable precipitating hydrophobic injectable liquid (PHIL) embolic agent enhanced with magnetic nanoparticles (IONPs) is used, which remains stable in physiological conditions and allows for repeated heating treatments by applying an alternating magnetic field, enabling precise and localized heating at the tumor site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Temperature
If magnetic nanoparticle solutions are injected for MFH treatment, then heating is produced at the target area, but the nanoparticle concentration decreases over time due to diffusion, reducing heating efficacy
Solution Approach 1:
The patent applies preliminary action by pre-loading magnetic nanoparticles into a carrier vehicle (such as microbubbles or liposomes) before injection. This pre-encapsulation ensures that the nanoparticles are delivered directly to the target area and remain concentrated there during the heating treatment, preventing the diffusion problem that occurs with direct nanoparticle injection.
Solution Approach 2:
The patent uses an intermediary carrier vehicle (microbubbles, liposomes, or other delivery vehicles) to mediate between the magnetic nanoparticles and the target tissue. This intermediary protects the nanoparticles from diffusion while allowing them to be delivered precisely to the tumor site and released in controlled manner for effective heating.
2Duration of action of moving object
If repeated MFH treatments are attempted, then tumor recurrence can be addressed, but nanoparticle diffusion and degradation make consistent heating difficult to achieve
Solution Approach 1:
The carrier vehicles are pre-prepared with magnetic nanoparticles before each treatment session, ensuring that fresh, concentrated nanoparticles are delivered to the target area for each repeated treatment. This eliminates the degradation and diffusion problems that would occur with repeated direct injections of free nanoparticles.
Solution Approach 2:
The patent changes the physical state and delivery parameters of the magnetic nanoparticles by encapsulating them in carrier vehicles. This allows the nanoparticles to maintain their concentration and heating properties over time, enabling reliable repeated treatments with consistent heating efficacy.
3Quantity of substance
If high concentration of magnetic NPs is maintained at target region, then heating efficacy is improved, but NP diffusion in bloodstream reduces the achievable concentration
Solution Approach 1:
The carrier vehicle acts as an intermediary that slows down and controls the release of magnetic nanoparticles at the target site. This prevents rapid diffusion into the bloodstream while maintaining high local concentration, allowing sufficient nanoparticles to accumulate for effective heating before they are released and gradually cleared.
Solution Approach 2:
The nanoparticles are pre-loaded into carrier vehicles that are designed to circulate stably in the bloodstream and then release their cargo at the target site. This preliminary encapsulation prevents premature diffusion while enabling controlled delivery, achieving high local concentration without the rapid loss that occurs with free nanoparticle injection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PHIL-IONP combination provides consistent and predictable heating without degradation, allowing for multiple thermal treatments based on tumor growth monitoring, thereby minimizing tumor recurrence and reducing damage to adjacent tissues.
Implementation Method 1
magnetic nanoparticles (NPs) are injected into an area of interest and then externally heated (due to magnetic hysteresis losses) in the presence of an alternating magnetic field (AMF)
Implementation Method 2
the interaction of electromagnetic fields with tissue induces eddy-current-based Joule heating, which is proportional to the frequency of these fields
Data Source
AI summary
A method and a system for thermally or hyperthermally treating an object. A precipitating hydrophobic injectable liquid (PHIL) embolic agent is prepared and enhanced with a magnetic nanoparticle (NP). A delivery device is advanced to a target area and the PHIL−IONP embolic agent is injected directly at the target area. The PHIL and IONPS are observed in-situ using complementary imaging and an impulse is applied to the target area to generate heat sufficient to thermally ablate or induce hyperthymia at the target area. Additional impulses applied to the target areas at later times generate heat sufficient to ablate or induce hyperthymia at the target.